Spero Therapeutics Inc (SPRO) Stock Price, Quote & News

Company Profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candi...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 242 1600

Website: sperotherapeutics.com

Address:

675 Massachusetts Avenue, 14th Floor, Cambridge, United States

Observerinvestor Dec. 5 at 1:55 AM

$SPRO Would that be before the NDA, after the NDA before the approval or after the approval? The question is not if, it is when.

0 · Reply

n44 Dec. 4 at 8:46 PM

$SPRO We have only 18 more trading days till the end of the month, 💰💰💰💰💰

0 · Reply

n44 Dec. 4 at 6:21 PM

$SPRO The money 💰 is keeping this in a tight hold, just churning the stock, everyone is waiting, release the Kraken!!!!!!!

0 · Reply

n44 Dec. 4 at 5:02 PM

$SPRO The stock is just trading sideways until the NDA is filed by GSK and then it will have a new direction. I can only hope that GSK is being very diligent in getting this done but at the same time, the company has had plenty of time, let’s get this DONE!!!!!!!!

0 · Reply

HedgeAlerts Dec. 4 at 7:51 AM

Hedge Alert Live - Protect Your Portfolio Contract: $SPRO $2.50 Put · DEC 19, 2025 Exp Entry Price: $0.29 - $0.60 Exit Price Target: $0.67 Profit Margin: +132% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

n44 Dec. 3 at 8:37 PM

$SPRO One would think now is the time to invest in Spero Therapeutics since the two companies Spero and GlaxoSmithKline have repeatedly said the NDA for Tebipenem will be filed before the end of this month. If GlaxoSmithKline were not involved in the NDA I would be more concerned about getting this done but I give them the benefit of the doubt, what the price will be is a crapshoot for me. I have been disappointed so many times in the past from these small companies like Spero who over promise and under deliver that all I can say is show me the money 💰💰💰💰

0 · Reply

DDel Dec. 3 at 7:00 PM

$SPRO a smart long patient investor never engages in whining. if you don't have confidence in what you own, either short it or sell your stock and move on. Mr. T. Rowe Price said it best, Invest with Confidence.

1 · Reply

Olg59 Dec. 3 at 4:54 PM

$SPRO Zacks gives APRO rank#2 BUY! https://www.zacks.com/stock/quote/SPRO

0 · Reply

Drashkawisha Dec. 3 at 2:44 PM

$SPRO We are in December. That means the GSK NDA filing is imminent (Q4 target). People forget what we hold here: 1. Big Pharma Partner: GSK is doing the heavy lifting. 2. Safety Net: Cash runway to 2028. Dilution is off the table. 3. Valuation: Trading at ~$2.30 with analysts targeting $5+. The disconnect is massive. This is a classic "coiled spring" setup. While retail gets bored, smart money waits for the PR drop. I’m fully loaded and waiting for the fireworks. Let the NDA news hit

0 · Reply

LiquidThetaOptions Dec. 3 at 6:58 AM

💎 LiquidTheta® Live Actionable Trade Asset: $SPRO Contracts: $SPRO July 17, 2026 $2 Calls Scale in: $0.62- $0.76 Scale out: $2.41-$4.12 Profit Potential : 227% ROI Blended Join 💎 Here: https://liquidtheta.com

0 · Reply

Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 13, 2025, 4:05 PM EST - 21 days ago

Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update

Nov 4, 2025, 4:05 PM EST - 4 weeks ago

Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025

Oct 21, 2025, 2:00 AM EDT - 6 weeks ago

PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Oct 14, 2025, 8:00 AM EDT - 7 weeks ago

Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek

Aug 12, 2025, 7:32 PM EDT - 4 months ago

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

Aug 12, 2025, 4:01 PM EDT - 4 months ago

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

Aug 5, 2025, 4:05 PM EDT - 4 months ago

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

Jun 11, 2025, 3:20 PM EDT - 6 months ago

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

May 28, 2025, 11:24 AM EDT - 6 months ago

Why Is GSK Partner Spero Therapeutics Stock Skyrocketing On Wednesday?

GSK

May 28, 2025, 7:00 AM EDT - 6 months ago

Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee

GSK

May 13, 2025, 4:01 PM EDT - 7 months ago

Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update

May 5, 2025, 8:00 AM EDT - 7 months ago

Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025

Apr 28, 2025, 4:01 PM EDT - 7 months ago

Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer

Mar 27, 2025, 8:31 PM EDT - 9 months ago

Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 4:01 PM EDT - 9 months ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Mar 18, 2025, 8:00 AM EDT - 9 months ago

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

Feb 25, 2025, 10:15 AM EST - 10 months ago

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Feb 25, 2025, 7:00 AM EST - 10 months ago

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Jan 19, 2025, 8:00 AM EST - 11 months ago

Spero Therapeutics: Undervalued Based On Just Tebipenem And GSK Deal

Jan 10, 2025, 7:00 AM EST - 11 months ago

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Nov 14, 2024, 4:05 PM EST - 1 year ago

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update

Oct 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024

Oct 2, 2024, 4:30 PM EDT - 1 year ago

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy

Aug 9, 2024, 10:47 AM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024

May 16, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference

May 15, 2024, 4:05 PM EDT - 1 year ago

Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update

May 8, 2024, 8:00 AM EDT - 1 year ago

Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024

May 1, 2024, 4:07 PM EDT - 1 year ago

Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Apr 23, 2024, 11:37 AM EDT - 1 year ago

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Mar 13, 2024, 5:45 PM EDT - 1 year ago

Spero Therapeutics, Inc. (SPRO) Q4 2023 Earnings Call Transcript

Mar 13, 2024, 4:01 PM EDT - 1 year ago

Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update

Mar 6, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024

Feb 28, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections

Feb 26, 2024, 8:05 AM EST - 1 year ago

Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference

Jan 5, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Provides Corporate Update and 2024 Outlook

Jan 2, 2024, 8:05 AM EST - 2 years ago

Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Nov 13, 2023, 7:05 PM EST - 2 years ago

Spero Therapeutics, Inc. (SPRO) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:05 AM EST - 2 years ago

Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 1, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer

Sep 20, 2023, 4:05 PM EDT - 2 years ago

Spero Therapeutics to Present at Cantor's Global Healthcare 2023 Investor Conference

Sep 6, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Aug 3, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 31, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr

Jul 5, 2023, 3:06 PM EDT - 2 years ago

Spero Therapeutics: The Multi-Asset Pipeline Could Outpace The Tebipenem HBr Deal With GSK

Jun 14, 2023, 8:05 AM EDT - 2 years ago

Spero Therapeutics Appoints Sath Shukla as President & Chief Executive Officer

Observerinvestor Dec. 5 at 1:55 AM

$SPRO Would that be before the NDA, after the NDA before the approval or after the approval? The question is not if, it is when.

0 · Reply

n44 Dec. 4 at 8:46 PM

$SPRO We have only 18 more trading days till the end of the month, 💰💰💰💰💰

0 · Reply

n44 Dec. 4 at 6:21 PM

$SPRO The money 💰 is keeping this in a tight hold, just churning the stock, everyone is waiting, release the Kraken!!!!!!!

0 · Reply

n44 Dec. 4 at 5:02 PM

0 · Reply

HedgeAlerts Dec. 4 at 7:51 AM

0 · Reply

n44 Dec. 3 at 8:37 PM

0 · Reply

DDel Dec. 3 at 7:00 PM

1 · Reply

Olg59 Dec. 3 at 4:54 PM

$SPRO Zacks gives APRO rank#2 BUY! https://www.zacks.com/stock/quote/SPRO

0 · Reply

Drashkawisha Dec. 3 at 2:44 PM

0 · Reply

LiquidThetaOptions Dec. 3 at 6:58 AM

0 · Reply

Inc82 Dec. 2 at 8:04 PM

$SPRO i don’t see an end to this bleeding.

0 · Reply

janed102 Dec. 2 at 7:53 PM

$SPRO date running out for BLA... December nearly at end and still no news.. they should provided an update before Xmas.

2 · Reply

Drashkawisha Dec. 2 at 4:27 PM

$SPRO Trading well below cash/value. The Tebipenem opportunity is being ignored by the market. At these levels, downside is limited, upside on any news is massive. Patience play.

1 · Reply

Inc82 Dec. 2 at 4:11 PM

$SPRO Something does not add up with this stock. Care to comment?

1 · Reply

mdboss Dec. 2 at 3:24 PM

$SPRO Tebi is too big to fail.

0 · Reply

Drashkawisha Dec. 2 at 3:19 PM

$SPRO Q3 Update: The Thesis is Stronger than Ever. Ignore the noise, focus on the data: ✅ Cash Runway into 2028: Dilution risk is OFF the table. ✅ GSK Partnership: NDA filing for Tebipenem HBr confirmed for THIS Quarter (Q4 2025). The clock is ticking. ✅ Streamlined Focus: Dropping SPR720 means 100% resources on the commercial winner (Tebipenem). ✅ Data: PIVOT-PO confirmed efficacy. Waiting for the "GSK Submits NDA" headline. Patiently holding.

0 · Reply

mdboss Dec. 2 at 3:14 PM

$SPRO I'm intrigued with the timing of this announcement and yes I'll take the bait. 90k RSUs. Huh?? Why not 100k or even 250k or 500k? It is my sense as I have previously speculated that this new hire is a very big cheese. Management receives salary in the millions and this dude gets tossed a measly $216K worth of options (priced at $2.40) .... really???? This feels like it wants to re-price much higher than any of us can imagine and if what I see is correct, Tebi will be a cash cow for GSK and if that's the case there is really no upper limit on the share price. I think the only real question is how greedy will management be.... and I'll be the first to say that I want $100 for each of my shares! #begreedy

0 · Reply

Autolus_Freakk Dec. 2 at 3:07 PM

$SPRO As soon as I buy this shit goes down..

0 · Reply

Inc82 Dec. 1 at 11:51 PM

$SPRO one step forward three steps backward. POS

0 · Reply

TheHookingBull Dec. 1 at 11:03 PM

$SPRO why is this sitting at $2 with an efficacy trial halt?

1 · Reply

HedgeAlerts Dec. 1 at 10:45 PM

Hedge Alert Live - Protect Your Portfolio Contract: $SPRO $2.50 Put · DEC 19, 2025 Exp Entry Price: $0.25 - $0.30 Exit Price Target: $0.59 Profit Margin: +138% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com

0 · Reply

Autolus_Freakk Dec. 1 at 8:58 PM

$SPRO GSK has no aim of taking over this company

1 · Reply

Market Cap	123.95M
Revenue (ttm)	47.98M
Net Income (ttm)	-68.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-142.91%
Debt to Equity Ratio	0.00

Volume	241,700
Avg Vol	732,876
Day's Range	N/A - N/A
Shares Out	56.34M
Stochastic %K	42%
Beta	1.48
Analysts	Sell
Price Target	$5.00